Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Adempas
Riociguat is a soluble guanylate cyclase (sGC) stimulator used to treat certain types of pulmonary hypertension. It works by directly stimulating sGC, an enzyme in the cardiopulmonary system that plays a crucial role in regulating vascular tone and remodeling. By enhancing sGC activity, riociguat increases the production of cyclic guanosine monophosphate (cGMP), leading to vasodilation and improved blood flow in the pulmonary arteries. It is categorized as a vasodilator.
For the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).
Riociguat is contraindicated in patients taking PDE5 inhibitors (e.g., sildenafil, tadalafil) due to the risk of severe hypotension. It should not be used during pregnancy due to potential harm to the fetus.
Outcome:
Severe hypotension
Mechanism:
Synergistic vasodilation
Outcome:
Increased riociguat levels
Mechanism:
Inhibition of CYP3A4
Outcome:
Delayed absorption
Mechanism:
Altered gastric emptying
Most likely new formulation: Long-acting injectable or implantable formulation (Year 2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a 75% likelihood of expanded indications for riociguat in other forms of pulmonary hypertension within the next 5 years.
sGC Stimulator, Vasodilator
Pyrazolopyridine